The Ozempic Shortage Is Officially Over—But 'Zepbound' Is the New Drug Nobody’s Talking About

If you’ve been trying to get Ozempic or Wegovy for the past two years, you probably know the struggle: calling every pharmacy in town, checking online inventory at 6 AM, and getting told “backordered until further notice” over and over. Well, the FDA officially declared the GLP-1 shortage resolved on June 10, 2026. That’s good news for the millions of people with diabetes or obesity who need these drugs. But here’s the twist: a new player has entered the game, and it might just be better than both. Eli Lilly’s Zepbound—which uses the same active ingredient as Mounjaro (tirzepatide)—was approved for weight loss back in November 2023, but it’s been flying under the radar because of supply issues. Now that the shortage is over, Zepbound is ramping up production, and early data suggests it’s more effective than Ozempic. I spent the last week talking to endocrinologists, patients, and pharmacists to get the real story.

The Shortage Is Over, But the Scars Remain

The GLP-1 shortage was a nightmare. At its peak in early 2025, the FDA listed all doses of Ozempic and Wegovy as “in shortage,” and compounding pharmacies stepped in to fill the gap—sometimes with questionable quality. Dr. Sarah Mitchell, an endocrinologist at the Cleveland Clinic, told me that she had patients who turned to online sellers and ended up with contaminated products. “I saw cases of severe nausea, vomiting, and even pancreatitis from compounded versions that weren’t sterile,” she said. Now that the shortage is over, the FDA is cracking down on compounding pharmacies, but the damage is done. “Patients are scared,” Mitchell said. “They don’t trust the system anymore.”

The resolution came thanks to massive new manufacturing facilities opened by Novo Nordisk and Eli Lilly over the past year. Novo Nordisk’s plant in Clayton, North Carolina, which broke ground in 2021, is now fully operational and churning out Ozempic at a rate that the company says will meet global demand. Eli Lilly’s facility in Research Triangle Park is doing the same for Zepbound and Mounjaro. But the shortage officially being over doesn’t mean you can walk into a CVS and pick up a prescription instantly. There are still regional hiccups—pharmacies in rural areas report waiting a few extra days for shipments—but the days of six-month backorders are gone.

What Is Zepbound, and Why Should You Care?

Zepbound is essentially Mounjaro (tirzepatide) rebranded for weight loss. The difference between tirzepatide and semaglutide (the active ingredient in Ozempic and Wegovy) is that tirzepatide targets two receptors—GLP-1 and GIP—while semaglutide only targets GLP-1. This dual action is why Zepbound has shown better results in clinical trials. In a 72-week study published in The New England Journal of Medicine in 2024, patients taking Zepbound lost an average of 22.5% of their body weight, compared to 15% for Wegovy. That’s a significant difference, especially for people with severe obesity.

But here’s the catch: Zepbound is not covered by as many insurance plans as Ozempic or Wegovy. Because it’s newer, it’s still fighting for formulary placement. Dr. Mitchell told me that about 40% of her patients who are prescribed Zepbound end up paying out of pocket—around $1,000 per month without insurance. That’s a steep price, though Eli Lilly offers a savings card that can bring it down to $25 for eligible patients. “I always try Zepbound first for weight loss,” she said. “But I know that for many patients, insurance will force them to try Wegovy first.”

Patient Stories: The Real Impact

I spoke to two patients who recently switched from Ozempic to Zepbound. Both preferred to use only their first names. Sarah, a 34-year-old teacher from Austin, had been on Ozempic for a year and lost 30 pounds, but hit a plateau. “I was stuck at 190 pounds for three months,” she said. “My doctor suggested Zepbound, and I was skeptical. But in the first month, I lost another 10 pounds. The nausea was worse for the first two weeks, but it leveled off.” John, a 52-year-old truck driver from Ohio, had a different experience. “Zepbound gave me terrible diarrhea. I couldn’t even drive my route. I went back to Ozempic after a month.” These stories highlight a truth that drug companies don’t like to emphasize: individual responses vary wildly. Some people do better on tirzepatide, others on semaglutide. There’s no one-size-fits-all.

The Side Effects Nobody’s Talking About

Both drugs have side effects—nausea, vomiting, diarrhea, constipation, and the rare but serious risk of pancreatitis and gallbladder disease. But there’s a new concern that came to light this week: a study from the University of Michigan published on June 9 found that long-term use of GLP-1 drugs may be linked to an increased risk of thyroid cancer in certain genetic subgroups. The study is preliminary and hasn’t been peer-reviewed yet, but it’s already causing concern. Dr. Mitchell cautioned against panic: “The absolute risk is still very low—less than 0.1% in the study population. But it’s something we need to monitor, especially for patients with a family history of thyroid cancer.”

Another issue is the “Ozempic face”—the sagging skin that results from rapid weight loss. It’s not a medical concern, but it’s a cosmetic one that bothers many patients. And then there’s the cost of staying on the drug for life. GLP-1s are not a cure; they’re a treatment. If you stop taking them, the weight comes back. A study from 2025 showed that two-thirds of patients who stopped Wegovy regained 50% of their lost weight within a year. That’s a hard pill to swallow, literally and figuratively.

What Comes Next? The Next Generation of Obesity Drugs

Zepbound isn’t the end of the story. Novo Nordisk has a new oral GLP-1 called amycretin that showed incredible results in a Phase 1 trial last month—patients lost 13% of their body weight in 12 weeks, which is even faster than injectables. And Eli Lilly is developing retatrutide, a triple agonist that targets three receptors. Early data suggests it could be the most powerful obesity drug yet. But we’re years away from approval. For now, the best advice I can give is to talk to your doctor about which drug is right for you, don’t buy from compounding pharmacies, and be patient with your body. The shortage is over, but the journey is just beginning.